Abdulmohsen Alruwetei

Dr. Abdulmohsen Alruwetei

Medical Laboratories Department, College of Applied Medical Sciences, Qassim University, Qassim, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Gene
Verified
Journal Article
Closed access
NBNouf Abubakr Babteen
Nouf Abubakr Babteen
Manal S. FawzyManal S. Fawzy
Manal S. Fawzy
WAWalla Alelwani
Walla Alelwani
RARaed Alharbi
Raed Alharbi
AAAbdulmohsen Alruwetei
Abdulmohsen Alruwetei
Rami ElshazliRami Elshazli
Rami Elshazli

1 August 2020 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
AKArif Khan
Arif Khan
AAAhmed N Aljarbou
Ahmed N Aljarbou
YAYousef H Aldebasi
Yousef H Aldebasi
Khaled S. AllemailemKhaled S. Allemailem
Khaled S. Allemailem
MAMohammed A Alsahli
Mohammed A Alsahli
Masood A KhanMasood A Khan
Masood A Khan
Purpose: The overexpression of Her-2 in 25– 30% breast cancer cases and the crosstalk between Her-2 and fatty acid synthase (FASN) establishes Her-2 as a promising target for site-directed delivery. The present study aimed to develop the novel lipid base formulations to target and inhibit the cellular proliferation of Her-2-expressing breast cancer cells through the silencing of FASN. In order to achieve this goal, we prepared DSPC/Chol and DOPE/CHEMS immunoliposomes, conjugated with the anti-Her-2 fab’ and encapsulated FASN siRNA against breast cancer cells. Methods: We evaluated the size, stability, cellular uptake and internalization of various formulations of liposomes. The antiproliferative gene silencing potential was investigated by the cell cytotoxicity, crystal violet, wound healing and Western blot analyses in Her-2+ and Her-2® breast cancer cells. Results: The data revealed that both nanosized FASN-siRNA-encapsulated liposomes showed significantly higher cellular uptake and internalization with enhanced stability. The cell viability of Her-2+ SK-BR3 cells treated with the targeted formulation of DSPC/Chol- and DOPE/CHEMS-encapsulating FASN-siRNA reduced to 30% and 20%, respectively, whereas it was found to be 45% and 36% in MCF-7 cells. The wounds were not only failed to close but they became broader in Her-2+ cells treated with targeted liposomes of siRNA. Consequently, the amount of FASN decreased by 80% in SK-BR3 cells treated with non-targeted liposomes and it was 30% and 60% in the MCF-7 cells treated with DSPC/Chol and DOPE/CHEMS liposomes, respectively. Conclusion: In this study, we developed the formulation that targeted Her-2 for the suppression of FASN and, therefore, inhibited the proliferation of breast cancer cells.

1 May 2020 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
SKShaheer Hasan Khan
Shaheer Hasan Khan
HYHina Younus
Hina Younus
Khaled S. AllemailemKhaled S. Allemailem
Khaled S. Allemailem
AAAhmad Almatroudi
Ahmad Almatroudi
FAFaris Alrumaihi
Faris Alrumaihi
Masood A KhanMasood A Khan
Masood A Khan
Background: Fungal infections are becoming more prevalent and threatening because of the continuous emergence of azole-resistant fungal infections. The present study was aimed to assess the activity of free Methylglyoxal (MG) or MG-conjugated chitosan nanoparticles (MGCN) against fluconazole-resistant Candida albicans. Materials and Methods: A novel formulation of MGCN was prepared and characterized to determine their size, shape and polydispersity index. Moreover, the efficacy of fluconazole or MG or MGCN was determined against intracellular C. albicans in macrophages and the systematic candidiasis in a murine model. The safety of MG or MGCN was tested in mice by analyzing the levels of hepatic and renal toxicity parameters. Results: Candida albicans did not respond to fluconazole, even at the highest dose of 20 mg/kg, whereas MG and MGCN effectively eliminated C. albicans from the macrophages and infected mice. Mice in the group treated with MGCN at a dose of 10 mg/kg exhibited a 90% survival rate and showed the lowest fungal load in the kidney, whereas the mice treated with free MG at the same dose exhibited 50% survival rate. Moreover, the administration of MG or MGCN did not induce any liver and kidney toxicity in the treated mice. Conclusion: The findings of the present work suggest that MGCN may be proved a promising therapeutic formulation to treat azole-resistant C. albicans infections.

1 August 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Ayman Mohamed Hasan MousaAyman Mohamed Hasan Mousa
Ayman Mohamed Hasan Mousa
AAAhmad Almatroudi
Ahmad Almatroudi
AAAmeen S Alwashmi
Ameen S Alwashmi
WAWaleed Alabdulmonem
Waleed Alabdulmonem
AAAbdullah S.M. Aljohani
Abdullah S.M. Aljohani
SASaleh Almatroodi
Saleh Almatroodi
Bronchial asthma (BA) is a heterogeneous allergic respiratory disease with diverse inflammatory symptoms, pathology, and responses to treatment. Thyme is a natural product which is consisted of multiple phenolic compounds of therapeutic significance for treatment of cough and bronchitis. This study evaluated the efficacy of thyme oil against ovalbumin (OVA)-induced BA in an experimental rabbit model. Forty male rabbits were divided into four equal groups [control group (G1), OVA (G2), thyme oil (G3), and OVA plus thyme oil (G4)]. Animals were treated for 30 days, and clinical, histopathological (HP), histochemical (HC), immunohistochemical (IHC), morphometric, biochemical and flow cytometry methods were performed, followed by statistical analysis. All used methods revealed normal structure of the lung tissues in rabbits of G1 and G3. In contrast, the clinical examination of G2 rabbits revealed an obvious increase in the respiratory rate, sneezing and wheezing, whereas the HP, HC and IHC techniques exhibited substantial inflammatory changes in the peribronchio-vascular lung tissues with thinning, degeneration, apoptosis (using the TUNEL assay), necrosis, and shedding of the airway epithelium. Furthermore, the morphometric results confirmed significant increases in the numbers of inflammatory cells, goblet cells, eosinophils and apoptotic cells from (12, 0, 2, 2 cells) to (34,10, 16, 18 cells) respectively, as well as the area percentage of collagen fiber deposition and immunoexpression of eotaxin-1/10 high power fields. Additionally, the biochemical results revealed significant increases in the serum levels of TSLP, IL-4, IL-5, IL-9, IL-13, IgE and eotaxin-1 cytokines from (140, 40, 15, 38, 120, 100, 48) pg./ml to (360, 270, 130, 85, 365, 398, 110) pg./ml respectively, while analysis of ROS by flow cytometry revealed remarkable oxidative stress effects in G2 rabbits. On the other hand, treatment of rabbits with thyme oil in G4 substantially alleviated all OVA-induced alterations. Overall, our findings indicate for the first time that thyme oil can ameliorate OVA-induced BA via its immunomodulatory, anti-inflammatory, antiapoptotic, and antioxidant effects on the lung tissues of rabbits.

1 August 2021 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
MKMohd Shahnawaz Khan
Mohd Shahnawaz Khan
FHFohad Mabood Husain
Fohad Mabood Husain
Fahad A. AlhumaydhiFahad A. Alhumaydhi
Fahad A. Alhumaydhi
AAAmeen S.S. Alwashmi
Ameen S.S. Alwashmi
TRTabish Rehman
Tabish Rehman
ASAnas Shamsi
Anas Shamsi

2 April 2020 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
SASalman Akhtar
Salman Akhtar
NANaseem Akhter
Naseem Akhter
MNMohammad Zeeshan Najm
Mohammad Zeeshan Najm
SDS.V.S Deo
S.V.S Deo
NSN.K. Shukla
N.K. Shukla
SHSyed Akhtar Husain
Syed Akhtar Husain
Background: CTCF encodes 11-zinc finger protein which is implicated in multiple tumors including the carcinoma of the breast. The Present study investigates the association of CTCF mutations and their expression in breast cancer cases. Methods: A total of 155 breast cancer and an equal number of adjacent normal tissue samples from 155 breast cancer patients were examined for CTCF mutation(s) by PCR-SSCP and automated DNA sequencing. Immunohistochemistry (IHC) method was used to analyze CTCF expression. Molecular findings were statistically analyzed with various clinicopathological features to identify associations of clinical relevance. Results: Of the total, 16.1% (25/155) cases exhibited mutation in the CTCF gene. Missense mutations Gln > His (G > T) in exon 1 and silent mutations Ser > Ser (C > T) in exon 4 of CTCF gene were analyzed. A significant association was observed between CTCF mutations and some clinicopathological parameters namely menopausal status (p = 0.02) tumor stage (p = 0.03) nodal status (p = 0.03) and ER expression (p = 0.04). Protein expression analysis showed 42.58% samples having low or no expression (+), 38.0% with moderate (++) expression and 19.35% having high (+++) expression for CTCF. A significant association was found between CTCF protein expression and clinicopathological parameters include histological grade (p = 0.04), tumor stage (p = 0.04), nodal status (p = 0.03) and ER status (p = 0.04). Conclusions: The data suggest that CTCF mutations leading to its inactivation significantly contribute to the progression of breast cancer.